APA (7th ed.) Citation

Stroh, J., Seckinger, A., Heider, M., Eichner, R., Emde-Rajaratnam, M., Salwender, H., . . . Bassermann, F. (2019). MCT1 as molecularly validated predictive marker for lenalidomide-maintenance therapy in multiple myeloma. Blood, 134, . https://doi.org/10.1182/blood-2019-130734

Chicago Style (17th ed.) Citation

Stroh, Jacob, et al. "MCT1 as Molecularly Validated Predictive Marker for Lenalidomide-maintenance Therapy in Multiple Myeloma." Blood 134 (2019). https://doi.org/10.1182/blood-2019-130734.

MLA (9th ed.) Citation

Stroh, Jacob, et al. "MCT1 as Molecularly Validated Predictive Marker for Lenalidomide-maintenance Therapy in Multiple Myeloma." Blood, vol. 134, 2019, https://doi.org/10.1182/blood-2019-130734.